Rising to the challenges of rare disease treatment

We are a late-stage biopharmaceutical company committed to developing and commercializing products to treat rare diseases where there is an unmet medical need.

Soligenix directly conducts all of its Phase 2 and 3 clinical studies, ensuring the highest data quality while streamlining timelines and budgets. Soligenix’s expertise in orphan and unmet medical need is reflected in our specialized recruitment strategies and clinical trial designs, as well as our refined regulatory approach.